Project Grant R00HD109419

Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $1.1M
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a research project entitled "Optimizing Developmental Outcomes in Early Childhood After Neonatal Opioid Withdrawal Syndrome." The $180,059 award, effective August 1, 2024, will fund a 5-year longitudinal study to assess the independent and moderating effects of positive childhood experiences (PCEs) and adverse childhood experiences...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $2,567,596 in funding from September 2024 to May 2029 to support a longitudinal study on the intergenerational impacts of adverse childhood experiences (ACEs) on the sexual, reproductive, and mental health of young adults in Malawi. The primary objectives are to: 1) estimate the longitudinal impacts of...
This Project Grant award of $149,000 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research (CFDA 93.865) program aims to examine the impact of longitudinal patterns of adverse childhood experiences (ACEs) on adolescent sexual and reproductive health. The research will utilize innovative analytic methods applied to longitudinal data from the Fragile Families and Child Wellbeing Study to: 1) uncover patterns of...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $164,561.00 to the University of California, Davis (UC Davis) to study the potential mediating role of cytokines and DNA methylation in the association between prenatal exposure to endocrine disrupting chemicals (EDCs) and the development of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children. The research aims to:...
This $200,310 project grant from the Department of Health and Human Services' National Institutes of Health National Institute on Aging will fund research into the differential impact of adverse childhood experiences and aging on brain health. Specifically, the Oklahoma State University grant will pursue two aims: 1) characterize cognitive performance across emerging and older adult cohorts stratified by ACEs, and 2) characterize brain-derived neurotrophic factor levels across the two age...
This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the federal Child Health and Human Development Extramural Research program (CFDA 93.865), provides $170,296 to Teachers College, Columbia University to conduct a longitudinal study examining the relationships among maternal stress, epigenetic aging, and cognitive/behavioral development in early childhood. The 2-year project aims to: 1) Investigate stress-related...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to investigate the relationship between early life immune responses and the intergenerational link of cardiometabolic outcomes. The $245,625 award to The Johns Hopkins University aims to: 1) identify early life immune response signatures linked to long-term cardiometabolic health; 2) examine the...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support a longitudinal, intergenerational study on the development and transmission of threat sensitivity as a risk factor for psychopathology in young children. The $681,690 award to The Children's Hospital of Philadelphia will fund a study assessing the neural, biological, and behavioral correlates of threat sensitivity in 300 mother-child dyads over a...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $193,752 to Boston Medical Center Corporation to implement and evaluate a video-coaching intervention called THRIVE to promote positive parenting behaviors among mothers with opioid use disorder (OUD). The goal is to test the effectiveness of this intervention in improving parenting and reducing child behavior problems for preschool-aged children, as well as...

MOTHERS' CHILDHOOD EXPERIENCES, MATERNAL SENSITIVITY, AND IMMUNE REGULATION IN YOUNG CHILDREN - ADVERSE CHILDHOOD EXPERIENCES (ACES) SUCH AS CHILDHOOD NEGLECT, ABUSE, AND EXPOSURE TO VIOLENCE, SUBSTANCE USE, OR MENTAL HEALTH PROBLEMS ARE ESTIMATED TO BE THE ROOT CAUSE OF 9 OF THE 10 LEADING CAUSES OF DEATH IN THE US. HIGH LEVELS OF ACES CAN LEAD TO LONG-TERM DISRUPTIONS IN IMMUNE FUNCTION AND GENETIC REGULATORY MECHANISMS. SENSITIVE PARENTING IS ESSENTIAL FOR PROTECTING INFANTS AND CHILDREN FROM THE IMPACT OF ACES. YET PARENTING CAN BE PARTICULARLY CHALLENGING WHEN PARENTS THEMSELVES HAVE A HISTORY OF ACES, WHICH CAN UNDERMINE THEIR CAPACITY TO PROVIDE SENSITIVE CARE. NEVERTHELESS, MANY EXPOSED TO ACES DO NOT DEVELOP POOR HEALTH OUTCOMES OR BECOME LESS SENSITIVE PARENTS. POSITIVE CHILDHOOD EXPERIENCES (PCES) OFTEN CO-OCCUR WITH ACES AND CAN BE AN IMPORTANT SOURCE OF RESILIENCE THAT BUFFERS THE DELETERIOUS EFFECTS OF ACES. HOWEVER, THE POSITIVE EFFECTS OF PCES AND THE BIOBEHAVIORAL MECHANISMS THROUGH WHICH PARENTS' ACES AND PCES TOGETHER SHAPE CHILD HEALTH REMAIN POORLY UNDERSTOOD. THE PROPOSED K99/R00 STUDY AIMS TO ELUCIDATE THE RELATIONSHIPS AMONG MOTHERS' ACES AND PCES, MATERNAL SENSITIVITY, AND IMMUNE REGULATION IN INFANTS (3 MONTHS) AND TODDLERS (12-36 MONTHS) OF MOTHERS WHO ARE LIVING WITH OPIOID DEPENDENCE, A HIGH-RISK GROUP THAT OFTEN ENCOUNTERS A HOST OF ADVERSITIES. THIS STUDY WILL BUILD ON AN NICHD-FUNDED RANDOMIZED CLINICAL TRIAL (R01HD098525) THAT TESTS THE EFFICACY OF THE ATTACHMENT AND BIOBEHAVIORAL CATCH-UP (ABC) INTERVENTION AMONG MOTHERS WITH OPIOID DEPENDENCE AND INFANTS WITH PERINATAL OPIOID EXPOSURE. ASSESSMENT OF CHILD IMMUNE REGULATION IS NOT CURRENTLY INCLUDED IN THE PARENT STUDY. LEVERAGING THE PARENT STUDY'S PRE-INTERVENTION DATA, THE K99 PHASE WILL INVESTIGATE THE ASSOCIATIONS BETWEEN 100 MOTHERS' ACES AND PCES, MATERNAL SENSITIVITY, AND THEIR 3-MONTH-OLD INFANTS' IMMUNE REGULATION, INDICATED BY SALIVARY C-REACTIVE PROTEIN (CRP) AND SECRETORY IMMUNOGLOBULIN A (SIGA). MY LONG-TERM CAREER GOAL IS TO BECOME AN INDEPENDENT INVESTIGATOR WHO INTEGRATES BIOLOGICAL AND BEHAVIORAL CONCEPTS AND METHODS TO PROMOTE THE HEALTH AND WELL-BEING OF FAMILIES AND YOUNG CHILDREN EXPOSED TO HIGH LEVELS OF ADVERSITY. MY PRIOR WORK HAS FOCUSED ON BEHAVIORAL PATHWAYS BY WHICH ACES AND PCES MAY TRANSMIT ACROSS GENERATIONS. TO DATE, I HAVE HAD LIMITED TRAINING IN RESEARCH USING BIOLOGICAL APPROACHES AND METHODS. I AM MOTIVATED TO EXPAND MY KNOWLEDGE AND SKILLS IN ASSESSING IMMUNE BIOMARKERS AND INTERVENTION RESEARCH THROUGH THE PROPOSED TRAINING AND RESEARCH DURING THE K99 PHASE. THIS WILL BUILD A STRONG FOUNDATION FOR THE R00 PHASE AND FACILITATE MY TRANSITION TO INDEPENDENCE. GUIDED BY THE ESTABLISHED CONSERVED TRANSCRIPTIONAL RESPONSE TO ADVERSITY GENOMIC FRAMEWORK, THE R00 PHASE AIMS TO DETERMINE HOW MOTHERS' ACES AND PCES ARE ASSOCIATED WITH TODDLERS' IMMUNE REGULATION AS INDICATED BY BOTH CELLULAR (SALIVARY CRP AND SIGA) AND TRANSCRIPTOMIC (IMMUNE CELL GENE EXPRESSION PROFILE) BIOMARKERS; THIS WILL BE ACCOMPLISHED BY PROSPECTIVELY FOLLOWING AT LEAST 80 TODDLERS ENROLLED IN THE PARENT STUDY AT AGES 12, 24, AND 36 MONTHS.

Posted 9/13/24